Cardiac Biomarkers

Cardiac Biomarkers


Global Cardiac Biomarkers Market to Reach US$28.0 Billion by 2030

The global market for Cardiac Biomarkers estimated at US$17.0 Billion in the year 2023, is expected to reach US$28.0 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2023-2030. Troponins (T & I), one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$11.2 Billion by the end of the analysis period. Growth in the Brain Natriuretic Peptide (BNPs) or NT-proBNP segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 12.0% CAGR

The Cardiac Biomarkers market in the U.S. is estimated at US$4.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.6 Billion by the year 2030 trailing a CAGR of 12.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Cardiac Biomarkers Market - Key Trends & Drivers Summarized

How Are Technological Innovations Transforming the Cardiac Biomarkers Market?

Technological innovations are driving significant advancements in the cardiac biomarkers market, enhancing diagnostic accuracy and patient outcomes. Developments in high-sensitivity assays and point-of-care testing devices have revolutionized the detection and monitoring of cardiac conditions. These technologies enable rapid and accurate measurement of biomarkers such as troponin, B-type natriuretic peptide (BNP), and C-reactive protein (CRP), facilitating early diagnosis and timely intervention for conditions like myocardial infarction and heart failure. The integration of multiplexing technologies allows simultaneous measurement of multiple biomarkers, providing comprehensive insights into a patient`s cardiac health. Additionally, advancements in genomics and proteomics are paving the way for personalized medicine approaches, where biomarker profiles guide individualized treatment plans. These technological strides are crucial in improving the effectiveness of cardiac care and are a key driver of market growth.

What Role Do Clinical Research and Regulatory Approvals Play in Market Dynamics?

Clinical research and regulatory approvals are fundamental to the dynamics of the cardiac biomarkers market. Rigorous clinical trials are essential for validating the efficacy and safety of new biomarkers and diagnostic technologies. Successful trial outcomes and subsequent regulatory approvals from agencies like the FDA and EMA significantly boost market confidence and adoption. Regulatory bodies also play a crucial role in setting standards for biomarker assays, ensuring their accuracy, reliability, and consistency across different platforms. The growing emphasis on evidence-based medicine and the need for high-quality diagnostic tools are driving investments in clinical research. Furthermore, regulatory frameworks that facilitate the approval and adoption of innovative diagnostic solutions are critical for market expansion. As new biomarkers and diagnostic technologies continue to receive regulatory clearance, the market is poised for substantial growth.

How Are Market Dynamics and Competitive Strategies Influencing Growth?

The cardiac biomarkers market is characterized by intense competition and strategic initiatives aimed at enhancing market position. Leading companies are investing in research and development to introduce novel biomarkers and advanced diagnostic technologies. Strategic partnerships, mergers, and acquisitions are common as companies seek to expand their product portfolios and market reach. Collaborations between diagnostic companies and research institutions facilitate the development of cutting-edge solutions and accelerate their commercialization. Additionally, companies are focusing on expanding their presence in emerging markets, where the prevalence of cardiovascular diseases is rising. Marketing strategies that emphasize the clinical benefits and improved patient outcomes associated with advanced biomarkers are crucial for driving market growth. The competitive landscape, marked by constant innovation and strategic moves, is a significant factor propelling the market forward.

What Are the Key Drivers of Growth in the Cardiac Biomarkers Market?

The growth in the cardiac biomarkers market is driven by several factors. The increasing prevalence of cardiovascular diseases worldwide is a primary driver, necessitating the development of effective diagnostic tools for early detection and management. Technological advancements in biomarker assays and point-of-care testing devices are enhancing diagnostic accuracy and facilitating timely intervention. The growing emphasis on personalized medicine and the integration of genomics and proteomics in cardiac care are driving the adoption of biomarker-based diagnostics. Regulatory approvals and successful clinical trials that validate the efficacy and safety of new biomarkers further encourage their use in clinical practice. Additionally, strategic initiatives by market players, including research and development investments, partnerships, and market expansion efforts, are fostering innovation and driving growth.

Select Competitors (Total 39 Featured) -
  • Abbott Diagnostics
  • Beckman Coulter Inc.
  • BG Medicine
  • bioMérieux SA
  • Boditech Med Inc.
  • Labsystems Diagnostics OY
  • LifeSign LLC
  • LSI Medience Corp.
  • Merck KGaA
  • Ortho-Clinical Diagnostics Inc.
  • Quidel Corporation
  • Randox Laboratories
  • Response Biomedical Corp.
  • Roche Diagnostics Corp.
  • Siemens Healthineers
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Cardiac Biomarkers - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Cardiovascular Diseases Propels Demand for Early Detection Tools
Advancements in Point-of-Care Testing Technologies Spur Adoption of Cardiac Biomarkers
Integration of AI in Diagnostic Platforms Enhances Accuracy and Speed of Biomarker Analysis
Shift Towards Personalized Medicine is Impacting the Cardiac Biomarkers Market
Innovations in Lab-on-a-Chip Devices Propel Point-of-Care Cardiac Testing
Clinical Trials Validating New Biomarkers Expand the Diagnostic Spectrum
Growing Use of Biomarkers in Drug Development and Clinical Trials Drives Demand
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Cardiac Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Cardiac Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Cardiac Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Troponins (T & I) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Troponins (T & I) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Troponins (T & I) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Brain Natriuretic Peptide (BNPs) or NT-proBNP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Brain Natriuretic Peptide (BNPs) or NT-proBNP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Brain Natriuretic Peptide (BNPs) or NT-proBNP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Myocardial Muscle Creatine Kinase (CK-MB) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Myocardial Muscle Creatine Kinase (CK-MB) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Myocardial Muscle Creatine Kinase (CK-MB) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Myoglobin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Myoglobin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Myoglobin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Ischemia-Modified Albumin (IMA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Ischemia-Modified Albumin (IMA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Ischemia-Modified Albumin (IMA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Laboratory Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Laboratory Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Laboratory Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Point-of-Care Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Point-of-Care Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Point-of-Care Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
JAPAN
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
CHINA
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
EUROPE
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
FRANCE
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: France 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
GERMANY
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Germany 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Italy 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
UNITED KINGDOM
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: UK 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Spain 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Russia 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Rest of Europe 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Cardiac Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
AUSTRALIA
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Australia 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
INDIA
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: India Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: India 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: South Korea 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
LATIN AMERICA
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Cardiac Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Cardiac Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Latin America 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Argentina 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Brazil 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Mexico 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Rest of Latin America 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
MIDDLE EAST
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Cardiac Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Cardiac Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Middle East 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Iran 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Israel 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Saudi Arabia 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: UAE 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Rest of Middle East 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
AFRICA
Cardiac Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Cardiac Biomarkers by Product - Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Cardiac Biomarkers by Product - Percentage Breakdown of Value Sales for Troponins (T & I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Ischemia-Modified Albumin (IMA) and Other Products for the Years 2014, 2024 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Africa 16-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings